Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD1… (NCT06839456) | Clinical Trial Compass
RecruitingPhase 1/2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
United States100 participantsStarted 2025-03-21
Plain-language summary
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
Who can participate
Age range1 Month – 25 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Disease for which allogeneic HSCT may be curative.
✓. Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS).
✓. Patients must be 25 years of age and less
✓. Evaluation for organ and infectious status as per our CTTS standard operating procedure.
✓. Signed consent by parent/guardian or able to give consent if 18 years of age and older.
✓. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP.
Exclusion criteria
✕. Patients who have performance score less than 60.
✕. No suitable donor available for mobilized peripheral stem cells.
✕. Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma.
What they're measuring
1
Evaluate number of patients with acute graft vs host disease (aGVHD)
Timeframe: Up to 100 days post-transplantation
2
Evaluate number of patients with chronic graft vs host disease (cGVHD)